Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

In this page

Clinical Trial

NCT05987423 Recruiting, Active
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease

Phase 3
Interventional

Disease

Disease type

Other

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

26/10/2023

Closing date

14/03/2025

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)
See more

Pr Daniel Böhringer

Representative

Germany

Anterior Segment Rare Eye Diseases (WG4)
Working Group Leader
See more

Pr Benedetto Falsini

Representative

Italy

See more

ERN EYE member investigating site

HCP : Principal investigators